Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Luxonus is a medical device manufacturing company that offers new imaging device with optical ultrasonic technology.
Cellusion is a biotechnology research firm that focuses on corneal endothelial regenerative medicine intended to improve eye vision.
Heartseed is a clinical- stage biotechnology firm that focuses on utilizing regenerative medicine to address heart disease.
K-Pharma creates pharmaceuticals by utilizing early-stage neuro regenerative medicine and iPS drug discovery.
FingerVision is a robotics company that specializes in the sale of tactile sensors, robot hands, and develops robot systems.
Alivexis is a biotechnology company that engages in the research and development of custom medicine for the pharmaceutical industry.
APB produces and markets next-generation lithium-ion batteries known for their high reliability and energy density.
Connect Japan is developing services that connect people.
AdipoSeeds is a healthcare company that creates platelets from fat tissue using stem cells to address global shortages.
SENSY is an artificial intelligence technology that offers AI-driven solutions that learn human sensitivity and provide fashion services.
Motion Lib is a developer of haptics technology intended to increase collaboration between humans and robots.
Himuka AM Pharma is a pharmaceutical company focusing on the development of Adrenomedullin derivatives.
Institution for a Global Society is a French graduate school with students from 70 countries around the world.
Keio Innovation Initiative has invested in 61 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Keio Innovation Initiative's top investment sectors include Health Care, Medical, Manufacturing, Medical Device, Biotechnology. The firm invests across 30 different industry categories.
Among tracked funding rounds, Alivexis received $20.4M in a Series C round. Keio Innovation Initiative's total known invested capital is $324.3M.
Keio Innovation Initiative's average investment size is $5.3M across its portfolio of 61 companies.
Recent Keio Innovation Initiative portfolio additions include Luxonus, Cellusion, Heartseed, K Pharma, FingerVision. These companies were founded in 2020 or later.